Eli Lilly is an AI play in disguise
The bull case for Eli Lilly is that it is leveraging AI partnerships and acquisitions to accelerate drug discovery and monetize stalled biotech IP, transforming it into a tech-like growth compounder.
The argument
The guest argued that Eli Lilly's 55% year-over-year revenue growth mirrors tech giants like Nvidia, driven by GLP-1 success and aggressive AI integrations. By partnering with Insilico, Isomorphic Labs, and Nvidia, Lilly is positioned to bolt AI onto existing biotech IP to push treatments over the finish line.
The thesis, stress-tested
✓ What validates it
- ✓Eli Lilly announces successful clinical trial results for an AI-designed molecule
- ✓Further M&A of distressed biotech IP by Eli Lilly
▸ Risks discussed
- ▸High valuation expectations
- ▸Clinical trial failures for AI-designed drugs
- ▸Regulatory hurdles in biotech
Hear it yourself
"I think at the end of the day, it's more of a fear factor that is also representation of the amount of information that we're getting as an overload and all of these negative things which just continue to be brought out. And one of the factors that I think is becoming more of an issue, I think countries of the world, particularly China, does not want The US to have an up, an optimism on AI. They want data centers to be stopped. It is a race towards getting global power of AI and actually being able to deploy it across the globe. And I think slowing it down here, making it more of a political thing, which seems to be working at least reflected in consumer confidence is just the nature of where we are."
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE